Oslo, Norway, 22 May 2025 In relation to the Annual General Meeting in Vistin Pharma ASA (OSE: VISTN), on the 22th of May, the Company’s Chair of the Board, Øyvin Brøymer, has received open proxies…
Exploratory analysis showed favorable patient-reported quality of life outcomes and delayed time to deterioration in…
– Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions…
– Updated data across two dose levels of 200 mW/cm and 400 mW/cm in LA-PDAC…
This positive CHMP opinion is based on results from the Phase 3 BREAKWATER trial, which…
May 29, 2026 21:18 ET | Source: Fobi AI Inc. VANCOUVER, BC, May 29, 2026…
MONACO, May 29, 2026 (GLOBE NEWSWIRE) -- Crypto news today is turning toward AlphaPepe as…